title: Protective effect of Tanshinone IIA against infarct size and increased HMGB1, NFκB, GFAP and apoptosis consequent to transient middle cerebral artery occlusion.
abstract: Acute inflammation plays an important role in brain damage following cerebral ischemia and reperfusion (I/R) injury. The present study employed a rat model of middle cerebral artery occlusion to explore the neuroprotective effects of tanshinone IIA (TSN), which is widely used in China for treating cerebrovascular and cardiovascular diseases. Rats were divided into a sham-operated group and I/R transiently occluded then reperfused groups. Some of the I/R animals were treated daily for 7 or 15 days with two different doses of TSN. After 15 days, triphenyl tetrazolium chloride staining revealed less unstained area indicating fewer lesions in the TSN-treated I/R group relative to the untreated corresponding I/R group. TSN treatment dramatically reduced infarct sizes and reduced content of high mobility group box 1 protein following I/R. Nuclear translocation of NFκB was also attenuated in I/R animals subsequently receiving TSN. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling staining revealed more apoptosis in the I/R model group and this was reduced in the I/R animals treated with TSN for 15 days. Thus, TSN mitigates the severity of damage effected by I/R.
authors.affiliation: Department of Neurology, The Third Xiang-Ya Hospital, Changsha, 410013, China.
authors.forename: Jian-Gang
authors.initials: JG
authors.lastname: Wang
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Bondy
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.forename: Feng-Zhen
authors.initials: FZ
authors.lastname: Yang
authors.forename: Zhi-Gang
authors.initials: ZG
authors.lastname: Ding
authors.forename: Yu
authors.initials: Y
authors.lastname: Hu
authors.forename: Yun
authors.initials: Y
authors.lastname: Tian
authors.forename: Pu-Yuan
authors.initials: PY
authors.lastname: Wen
authors.forename: Hao
authors.initials: H
authors.lastname: Luo
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.forename: Wen-Wen
authors.initials: WW
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Zhou
mesh_terms: D045784:Abietanes / Q000494:pharmacology*; D000818:Animals; D015153:Blotting, Western; D002544:Cerebral Infarction / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism*; D024243:HMGB1 Protein / Q000378:metabolism*; D020287:In Situ Nick-End Labeling; D020244:Infarction, Middle Cerebral Artery / Q000378:metabolism*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D045784:Abietanes; D005904:Glial Fibrillary Acidic Protein; D024243:HMGB1 Protein; C104200:Hbp1 protein, rat; D016328:NF-kappa B; D018696:Neuroprotective Agents; C021751:tanshinone